Rallybio Statistics
Total Valuation
Rallybio has a market cap or net worth of $41.24 million. The enterprise value is -$33.67 million.
Important Dates
The last earnings date was Thursday, November 7, 2024, before market open.
Earnings Date | Nov 7, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Rallybio has 41.49 million shares outstanding. The number of shares has increased by 8.55% in one year.
Current Share Class | 41.49M |
Shares Outstanding | 41.49M |
Shares Change (YoY) | +8.55% |
Shares Change (QoQ) | +1.05% |
Owned by Insiders (%) | 5.58% |
Owned by Institutions (%) | 26.81% |
Float | 18.98M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 70.71 |
Forward PS | n/a |
PB Ratio | 0.58 |
P/TBV Ratio | 0.58 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 9.55, with a Debt / Equity ratio of 0.00.
Current Ratio | 9.55 |
Quick Ratio | 9.18 |
Debt / Equity | 0.00 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -68.90% and return on invested capital (ROIC) is -42.74%.
Return on Equity (ROE) | -68.90% |
Return on Assets (ROA) | -39.29% |
Return on Capital (ROIC) | -42.74% |
Revenue Per Employee | $13,907 |
Profits Per Employee | -$1.56M |
Employee Count | 43 |
Asset Turnover | 0.01 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.05% in the last 52 weeks. The beta is -1.67, so Rallybio's price volatility has been lower than the market average.
Beta (5Y) | -1.67 |
52-Week Price Change | -50.05% |
50-Day Moving Average | 1.07 |
200-Day Moving Average | 1.44 |
Relative Strength Index (RSI) | 43.76 |
Average Volume (20 Days) | 70,041 |
Short Selling Information
The latest short interest is 463,356, so 1.12% of the outstanding shares have been sold short.
Short Interest | 463,356 |
Short Previous Month | 536,633 |
Short % of Shares Out | 1.12% |
Short % of Float | 2.44% |
Short Ratio (days to cover) | 5.75 |
Income Statement
In the last 12 months, Rallybio had revenue of $598,000 and -$66.97 million in losses. Loss per share was -$1.57.
Revenue | 598,000 |
Gross Profit | 6.10M |
Operating Income | -66.70M |
Pretax Income | -73.88M |
Net Income | -66.97M |
EBITDA | -66.56M |
EBIT | -66.70M |
Loss Per Share | -$1.57 |
Full Income Statement Balance Sheet
The company has $75.14 million in cash and $230,000 in debt, giving a net cash position of $74.91 million or $1.81 per share.
Cash & Cash Equivalents | 75.14M |
Total Debt | 230,000 |
Net Cash | 74.91M |
Net Cash Per Share | $1.81 |
Equity (Book Value) | 70.82M |
Book Value Per Share | 1.71 |
Working Capital | 70.04M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$51.07 million and capital expenditures -$12,000, giving a free cash flow of -$51.08 million.
Operating Cash Flow | -51.07M |
Capital Expenditures | -12,000 |
Free Cash Flow | -51.08M |
FCF Per Share | -$1.23 |
Full Cash Flow Statement Margins
Gross Margin | 1,019.40% |
Operating Margin | -11,153.85% |
Pretax Margin | -11,199.50% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | -18,061.20% |
Dividends & Yields
Rallybio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -8.55% |
Shareholder Yield | -8.55% |
Earnings Yield | -162.39% |
FCF Yield | -123.84% |
Analyst Forecast
The average price target for Rallybio is $8.10, which is 714.81% higher than the current price. The consensus rating is "Buy".
Price Target | $8.10 |
Price Target Difference | 714.81% |
Analyst Consensus | Buy |
Analyst Count | 6 |
Revenue Growth Forecast (5Y) | n/a |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
Rallybio has an Altman Z-Score of -1.2 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -1.2 |
Piotroski F-Score | 1 |